Top Health Tech Companies in Bengaluru (113)

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Strong Revenue Growth: Reported year-over-year software growth in 2024, alongside multi-year increases and net new client additions, indicates sustained commercial momentum. Customer penetration among large pharma is described as expanding across 2024–2025.

Investor Backing & Capital Strength: A majority investment by GI Partners, with Summit Partners remaining a minority investor, is described as supporting further scale, product investment, and global reach. This signals access to resources for continued expansion.

Strong Market Position & Advantage: Independent recognition as the highest-designated Leader in 2024 for life sciences clinical data and analytics platforms, coupled with adoption by numerous top biopharma companies, signals competitive strength in its core segment. Named client expansions further reinforce visibility and impact.

Strong Revenue Growth: Revenue increased substantially in 2024 to $6.06 billion, with quarterly results showing robust year-over-year gains. Membership on the platform also expanded meaningfully by year-end 2024, supporting the top line.

Strong Market Position & Advantage: The company operates one of the larger physician-enablement platforms focused on full-risk Medicare seniors, with a national footprint across 30+ communities and hundreds of thousands of covered lives. Its specialization in partnering with independent groups under global risk distinguishes it from broader, lighter-risk enablement peers.

Strategic Partnerships: Long-term arrangements with independent physician groups continued to expand with new marquee partners and entries into additional states. The partnership model provides aligned incentives and supports physician demand for enablement in value-based care.

Strong Market Position & Advantage: Analyst and client recognitions position EPAM as a leader in digital engineering and AI-enabled transformation, including multiple IDC MarketScape leadership placements and a Gartner recognition for custom software development. Independent coverage likewise describes the firm as a leading provider in these segments, reinforcing a durable competitive footing.

Resilient & Sustainable Growth: Revenue continues to expand year over year in recent quarters and on a trailing-twelve-month basis, and management still guides to growth for the current year despite a tougher backdrop. The pace has moderated compared with the prior year, but the trajectory remains positive.

Innovation-Driven Growth: The company is leaning into AI-native services and is identified as a leader in AI transformation engineering alongside strengths in data modernization and software engineering. This innovation-led mix is presented as a key engine for future expansion.

Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.

Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.

Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.

Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.

Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.

Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.

Strong Market Position & Advantage: Feedback suggests Illumina maintains dominant leadership in short-read NGS with a broad installed base, end-to-end workflows, and wide adoption across research and clinical markets. This entrenched position supports recurring consumables pull-through and reinforces competitive advantage.

Profitability: Feedback suggests profitability and margins improved with a stronger year-end quarter, rising EPS, and robust free cash generation supporting restructuring and reinvestment. Operating performance strengthened year over year, indicating better cost discipline and a healthier earnings profile.

Innovation-Driven Growth: Feedback suggests product and technology innovation—including NovaSeq X adoption and advances in AI/informatics—is driving utilization and clinical momentum. Partnerships and acquisitions broaden multiomics capabilities and underpin a roadmap focused on further cost and throughput gains.